Consensus conference on clinical practice in chronic GVHD: Second-line treatment of chronic graft-versus-host disease

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 1, 2011, Pages 1-17

  Wolff, Daniel ^a   Schleuning, Michael ^b   von Harsdorf, Stephanie ^c   Bacher, Ulrike ^d   Gerbitz, Armin ^e   Stadler, Michael ^f   Ayuk, Francis ^d   Kiani, Alexander ^g   Schwerdtfeger, Rainer ^b   Vogelsang, Georgia B ^h   Kobbe, Guido ⁱ   Gramatzki, Martin ^j   Lawitschka, Anita ^k   Mohty, Mohamad ^l   Pavletic, Steven Z ^m   Greinix, Hildegard ⁿ   Holler, Ernst ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b DKD   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ HEINRICH HEINE UNIVERSITY   (Germany)

^j UNIVERSITY OF KIEL   (Germany)

^k ST ANNA CHILDREN S HOSPITAL   (Austria)

^l UNIVERSITÉ DE NANTES   (France)

^m NATIONAL CANCER INSTITUTE   (United States)

ⁿ MEDICAL UNIVERSITY OF VIENNA   (Austria)

more..

Author keywords

Allogeneic hematopoietic stem cell transplantation; Bone marrow transplantation; Chronic GVHD; Immunosuppressive therapy

Indexed keywords

ALEFACEPT; ALEMTUZUMAB; BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; CLOFAZIMINE; CYCLOPHOSPHAMIDE; ETANERCEPT; EVEROLIMUS; HYDROXYCHLOROQUINE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PREDNISONE; RAPAMYCIN; RETINOL DERIVATIVE; RITUXIMAB; STEROID; THALIDOMIDE;

ARTICLE; AVASCULAR NECROSIS; BLOOD TOXICITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL PRACTICE; CONSENSUS; CONSTIPATION; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EXTRACORPOREAL PHOTOPHERESIS; FIBROSIS; FLUID RETENTION; GASTROINTESTINAL DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERPIGMENTATION; HYPERTENSION; INFECTION; IRRADIATION; MICROANGIOPATHY; MORBIDITY; MORTALITY; NEPHROTOXICITY; NEUROTOXICITY; OSTEOPOROSIS; PATIENT SELECTION; PRACTICE GUIDELINE; PSORIASIS; PUVA; RETROSPECTIVE STUDY; SALVAGE THERAPY; SIDE EFFECT; TRANSPLANTATION ASSOCIATED MICROANGIOPATHIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CHRONIC DISEASE; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DRUG THERAPY; GRAFT VERSUS HOST REACTION; METHODOLOGY; PATHOLOGY; PERSONALIZED MEDICINE;

CHRONIC DISEASE; DRUG THERAPY; FIBROSIS; GRAFT VS HOST DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; SALVAGE THERAPY;

EID: 79955632748     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.05.011     Document Type: Article

References (160)

1. Akpek G, Lee SM, Anders V, Vogelsang GB. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2001;7:495-502.
2. Akpek G, Zahurak ML, Piantadosi S, et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood. 2001;97:1219-1226.
3. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood. 2001;97:1196-1201.
4. Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006;12:375-396.
5. Schultz KR, Miklos DB, Fowler D, et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant. 2006; 12:126-137.
6. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945-956.
7. Martin PJ, Weisdorf D, Przepiorka D, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant. 2006;12:491-505.
8. Shulman HM, Kleiner D, Lee SJ, et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant. 2006;12:31-47.
9. Pavletic SZ, Martin P, Lee SJ, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant. 2006;12:252-266.
10. Couriel DR. Ancillary and supportive care in chronic graftversus-host disease. Best Pract Res Clin Haematol. 2008;21: 291-307.
11. AroraM, Wagner JE, DaviesSM, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versushost disease. Biol Blood Marrow Tranplant. 2001;7:265-273.
12. Koc S, Leisenring W, Flowers ME, et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood. 2000;96:3995-3996.
13. Martin PJ, Storer BE, Rowley SD, et al. evaluation of mycophenolate mofetil for initial treatment of chronic graftversus-host disease. Blood. 2009;113:5074-5082.
14. Mitchell SA, Leidy NK, Mooney KH, et al. Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graftversus-host disease (cGVHD). Bone Marrow Transplant. 2010; 45:762-769.
15. Goldberg JD, Jacobsohn DA, Margolis J, et al. Pentostatin for the treatment of chronic graft-versus-host disease in children. J Pediatr Hematol Oncol. 2003;25:584-588.
16. Robin M, Guardiola P, Girinsky T, et al. Low-dose thoracoabdominal irradiation for the treatment of refractory chronic graft-versus-host disease. Transplantation. 2005;80:634-642.
17. Jacobsohn DA, Chen AR, Zahurak M, et al. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. J Clin Oncol. 2007;25:4255-4261.
18. Couriel DR, Saliba R, Escalon MP, et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol. 2005;130:409-417.
19. Marcellus DC, Altomonte VL, Farmer ER, et al. Etretinate therapy for refractory sclerodermatous chronic graft-versushost disease. Blood. 1999;93:66-70.
20. Carella AM, D'Arena G, Greco MM, Nobile M, Cascavilla N. Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura. Bone Marrow Transplant. 2008;41:1063-1065.
21. Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2009;15:1005-1013.
22. Zaja F, Russo D, Fuga G, Perella G, Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology. 2000;55:1062-1063.
23. Johnston LJ, Brown J, Shizuru JA, et al. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11:47-55.
24. Benito AI, Furlong T, Martin PJ, et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation. 2001;72:1924-1929.
25. Wolff D, Bertz H, Stadler M, et al. Sirolimus in treatment of steroid refractory chronic GVHD-results on an interim analysis of a German multicentre phase II study. Bone Marrow Transplant. 2006;37(Suppl 1):S86.
26. Wolff D, Herzberg P, Heussner P, et al. Chronic GvHD of the lung significantly impairs quality of life and the activity profile- results of a prospective German multicentre validation trial. Bone Marrow Transplant. 2009;43(Suppl 1):128.
27. Busca A, Locatelli F, Marmont F, Audisio E, Falda M. Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease. Haematologica. 2003;88:837-839.
28. Flowers ME, Apperley JF, van Besien K, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008;112:2667-2674.
29. Greinix HT, Volc-Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood. 1998; 92:3098-3104.
30. Lopez F, Parker P, Nademanee A, et al. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11:307-313.
31. Kanamaru A, Takemoto Y, Kakishita E, et al. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. Bone Marrow Transplant. 1995;15:885-889.
32. Tzakis AG, Abu-Elmagd K, Fung JJ, et al. FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. Transplant Proc. 1991;23:3225-3227.
33. Carnevale-Schianca F, Martin P, Sullivan K, et al. Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2000;6: 613-620.
34. Przepiorka D, Blamble D, Hilsenbeck S, Danielson M, Krance R, Chan KW. Tacrolimus clearance is age-dependent within the pediatric population. Bone Marrow Transplant. 2000;26:601-605.
35. ApisarnthanaraxN, DonatoM, KorblingM, et al. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant. 2003;31:459-465.
36. Bisaccia E, Palangio M, Gonzalez J, Adler KR, Rowley SD, Goldberg SL. Treating refractory chronic graft-versus-host disease with extracorporeal photochemotherapy. Bone Marrow Transplant. 2003;31:291-294.
37. Child FJ, Ratnavel R, Watkins P, et al. Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD). Bone Marrow Transplant. 1999;23:881-887.
38. Couriel DR, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006;107:3074-3080.
39. Dall'Amico R, Messina C. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther Apher. 2002;6:296-304.
40. Foss FM, DiVenuti GM, Chin K, et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroidresistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant. 2005;35:1187-1193.
41. Gorgun G, Miller KB, Foss FM. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood. 2002;100:941-947.
42. Greinix HT, Volc-Platzer B, Kalhs P, et al. Extracorporeal photochemotherapy in the treatment of severe steroidrefractory acute graft-versus-host disease: a pilot study. Blood. 2000;96:2426-2431.
43. Greinix HT, Socie G, Bacigalupo A, et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant. 2006;38:265-273.
44. Kanold J, Messina C, Halle P, et al. Update on extracorporeal photochemotherapy for graft-versus-host disease treatment. Bone Marrow Transplant. 2005;35(Suppl 1):S69-S71.
45. Peritt D. Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12(1 Suppl 2):7-12.
46. SeatonED, SzydloRM, Kanfer E, Apperley JF, Russell-Jones R. Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood. 2003;102:1217-1223.
47. Gatza E, Rogers CE, Clouthier SG, et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood. 2008;112:1515-1521.
48. Perseghin P, Galimberti S, Balduzzi A, et al. Extracorporeal photochemotherapy for the treatment of chronic graftversus-host disease: trend for a possible cell dose-related effect? Ther Apher Dial. 2007;11:85-93.
49. Salvaneschi L, Perotti C, Zecca M, et al. Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. Transfusion. 2001;41:1299-1305.
50. Messina C, Locatelli F, Lanino E, et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol. 2003;122:118-127.
51. Kanold J, Merlin E, Halle P, et al. Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature. Transfusion. 2007;47:2276-2289.
52. Perseghin P, Dassi M, Balduzzi A, Rovelli A, Bonanomi S, Uderzo C. Mononuclear cell collection in patients undergoing extra-corporeal photo-chemotherapy for acute and chronic graft-vs.-host-disease (GvHD): comparison between COBE Spectra version 4.7 and 6.0 (AutoPBSC). J Clin Apher. 2002; 17:65-71.
53. Perutelli P, Rivabella L, Lanino E, Pistoia V, Dini G. ATP downregulation in mononuclear cells from children with graft-versus-host disease following extracorporeal photochemotherapy. Haematologica. 2002;87:335-336.
54. Rossetti F, Dall'Amico R, Crovetti G, et al. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Bone Marrow Transplant. 1996;18(Suppl 2):175-181.
55. Lee SJ, Vogelsang G, Gilman A, et al. A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant. 2002;8:32-39.
56. Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone MarrowTransplant. 1999;24:517-520.
57. Basara N, Blau WI, Romer E, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant. 1998;22:61-65.
58. Baudard M, Vincent A, Moreau P, Kergueris MF, Harousseau JL, Milpied N. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant. 2002;30:287-295.
59. Busca A, Saroglia EM, Lanino E, et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplant. 2000;25:1067-1071.
60. Furlong T, Martin P, Flowers ME, et al. Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant. 2009;44:739-748.
61. Kim JG, Sohn SK, Kim DH, et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol. 2004;73:56-61.
62. Krejci M, Doubek M, Buchler T, Brychtova Y, Vorlicek J, Mayer J. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol. 2005;84:681-685.
63. Parfitt JR, Jayakumar S, Driman DK. Mycophenolate mofetilrelated gastrointestinal mucosal injury: variable injury patterns, including graft-versus-host disease-like changes. Am J Surg Pathol. 2008;32:1367-1372.
64. Hambach L, Stadler M, Dammann E, Ganser A, Hertenstein B. Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;29:903-906.
65. Kirken RA, Wang YL. Molecular actions of sirolimus: sirolimus and mTor. Transplant Proc. 2003;35(Suppl 3):227S-230S.
66. Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD41CD251 regulatory T-cell function by calcineurindependent interleukin-2 production. Blood. 2006;108:390-399.
67. Chapman JR, Valantine H, Albanell J, et al. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc. 2007;39:2937-2950.
68. Schleuning M, Judith D, Jedlickova Z, et al. Calcineurin inhibitor-free GVHDprophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study. Bone Marrow Transplant. 2009;43:717-723.
69. Jurado M, Vallejo C, Perez-Simon JA, et al. Sirolimus as part of immunosuppressive therapy for refractory chronic graftversus-host disease. Biol Blood Marrow Transplant. 2007;13: 701-706.
70. Jedlickova Z, Burlakova I, Cook A, Baurmann H, Schwerdtfeger R, Schleuning M. mTOR inhibitors for treatment of sclerodermatous chronic graft-versus-host disease following allogeneic stem cell transplantation. Bone Marrow Transplant. 2009;43(Suppl):123.
71. Recher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood. 2005;105: 2527-2534.
72. Klink A, Schilling K, Rapp K, Höffken K, Sayer HG. High overall response rate in calcineurin inhibitor-free treatment with the mTOR inhibitor everolimus in advanced extensive chronic GvHD after allogeneic stem cell transplantation. Blood. 2008;112(Suppl):2210.
73. Kuppahally S, Al Khaldi A, Weisshaar D, et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant. 2006;6(5 Pt 1):986-992.
74. Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12: 552-559.
75. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr.. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem. 2001;276: 22382-22387.
76. Lepper ER, Smith NF, Cox MC, Scripture CD, Figg WD. Thalidomide metabolism and hydrolysis: mechanisms and implications. Curr Drug Metab. 2006;7:677-685.
77. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med. 1992;326:1055-1058.
78. Browne PV, Weisdorf DJ, Defor T, et al. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant. 2000;26:865-869.
79. Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood. 1995; 86:3604-3609.
80. Kulkarni S, Powles R, Sirohi B, et al. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant. 2003;32:165-170.
81. Rovelli A, Arrigo C, Nesi F, et al. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Bone Marrow Transplant. 1998;21:577-581.
82. Gilman AL, Chan KW, Mogul A, et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2000;6:327-334.
83. Estes ML, Ewing-Wilson D, Chou SM, et al. Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med. 1987;82:447-455.
84. Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus. 1996; 5(Suppl 1):S11-S15.
85. Miller DR, Khalil SK, Nygard GA. Steady-state pharmacokinetics of hydroxychloroquine in rheumatoid arthritis patients. DICP. 1991;25:1302-1305.
86. Epstein JB, Gorsky M, Epstein MS, Nantel S. Topical azathioprine in the treatment of immune-mediated chronic oral inflammatory conditions: a series of cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91:56-61.
87. Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988;72:546-554.
88. Curtis RE, Metayer C, Rizzo JD, et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood. 2005;105:3802-3811.
89. Jetten AM, Jetten ME, Shapiro SS, Poon JP. Characterization of the action of retinoids on mouse fibroblast cell lines. Exp Cell Res. 1979;119:289-299.
90. Ohta A, Uitto J. Procollagen gene expression by scleroderma fibroblasts in culture. Inhibition of collagen production and reduction of pro alpha 1(I) and pro alpha 1(III) collagen messengerRNAsteady-state levels by retinoids. Arthritis Rheum. 1987; 30:404-411.
91. Mucida D, Pino-Lagos K, Kim G, et al. Retinoic acid can directly promote TGF-beta-mediated Foxp3(1) Treg cell conversion of naive T cells. Immunity. 2009;30:471-472.
92. Xiao S, Jin H, Korn T, et al. Retinoic acid increases Foxp31 regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J Immunol. 2008;181: 2277-2284.
93. Ghoreschi K, Thomas P, Penovici M, et al. PUVA-bath photochemotherapy and isotretinoin in sclerodermatous graftversus-host disease. Eur J Dermatol. 2008;18:667-670.
94. Bahmer FA, Zaun H. Isotretinoin therapy for progressive systemic sclerosis. Arch Dermatol. 1985;121:308.
95. Bunker CB, Maurice PD, Little S, Johnson NM, Dowd PM. Isotretinoin and lung function in systemic sclerosis. Clin Exp Dermatol. 1991;16:11-13.
96. Maurice PD, Bunker CB, Dowd PM. Isotretinoin in the treatment of systemic sclerosis. Br J Dermatol. 1989;121:367-374.
97. Teachey DT, Bickert B, Bunin N. Daclizumab for children with corticosteroid refractory graft-versus-host disease. Bone Marrow Transplant. 2006;37:95-99.
98. Willenbacher W, Basara N, Blau IW, Fauser AA, Kiehl MG. Treatment of steroid refractory acute and chronic graftversus-host disease with daclizumab. Br J Haematol. 2001; 112:820-823.
99. Auffermann-Gretzinger S, Eger L, Schetelig J, Bornhauser M, Heidenreich F, Ehninger G. Alemtuzumab depletes dendritic cells more effectively in blood than in skin: a pilot study in patients with chronic lymphocytic leukemia. Transplantation. 2007;83:1268-1272.
100. Klangsinsirikul P, Carter GI, Byrne JL, Hale G, Russell NH. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood. 2002;99: 2586-2591.
101. Gribben JG, Hallek M.Rediscoveringalemtuzumab: current and emerging therapeutic roles. Br J Haematol. 2009;144:818-831.
102. Thomson KJ, Morris EC, Bloor A, et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2009;27:426-432.
103. Malladi RK, Peniket AJ, Littlewood TJ, et al. Alemtuzumab markedly reduces chronicGVHDwithout affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML. Bone Marrow Transplant. 2009;43:709-715.
104. Ruiz-Arguelles GJ, Gil-Beristain J, Magana M, Ruiz-Delgado GJ. Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008;14:7-9.
105. Schnitzler M, Hasskarl J, Egger M, Bertz H, Finke J. Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biol Blood Marrow Transplant. 2009;15:910-918.
106. Martinez C, Solano C, Ferra C, Sampol A, Valcarcel D, Perez-Simon JA. Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study. Biol Blood Marrow Transplant. 2009;15:639-642.
107. Park SH, Choi SM, Lee DG, et al. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin. Transpl Infect Dis. 2009;11:413-423.
108. Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis. 2007; 44:204-212.
109. Ratanatharathorn V, Carson E, Reynolds C, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med. 2000;133:275-279.
110. Ship A, May W, Lucas K. Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T celldepleted, haplo-identical stem cell transplantation. Bone Marrow Transplant. 2002;29:365-366.
111. Szabolcs P, Reese M, Yancey KB, Hall RP, Kurtzberg J. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versushost disease. Bone Marrow Transplant. 2002;30:327-329.
112. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ, van denTweel JG, Verdonck LF. Anti-CD20monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood. 2004;104:2603-2606.
113. Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003;9:505-511.
114. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroidrefractory chronic graft-versus-host disease. Blood. 2006;108: 756-762.
115. Carella AM, Biasco S, Nati S, Congiu A, Lerma E. Rituximab is effective for extensive steroid-refractory chronic graft-vs.-hostdisease. Leuk Lymphoma. 2007;48:623-624.
116. Mohty M, Marchetti N, El Cheikh J, Faucher C, Furst S, Blaise D. Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant. 2008;41:909-911.
117. Okamoto M, Okano A, Akamatsu S, et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versushost disease. Leukemia. 2006;20:172-173.
118. Teshima T, Nagafuji K, Henzan H, et al. Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. Int J Hematol. 2009;90:253-260.
119. Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronicGVHDwith rituximab: a GITMO study. Bone Marrow Transplant. 2007;40:273-277.
120. von Bonin M, Oelschlagel U, Radke J, et al. Treatment of chronic steroid-refractory graft-versus-host disease with lowdose rituximab. Transplantation. 2008;86:875-879.
121. Shapira MY, Abdul-Hai A, Resnick IB, et al. Alefacept treatment for refractory chronic extensive GVHD. Bone Marrow Transplant. 2009;43:339-343.
122. Stotler CJ, Eghtesad B, Hsi E, Silver B. Rapid resolution of GVHD after orthotopic liver transplantation in a patient treated with alefacept. Blood. 2009;113:5365-5366.
123. Toor AA, Stiff PJ, Nickoloff BJ, Rodriguez T, Klein JL, Gordon KB. Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. J Dermatolog Treat. 2007;18:13-18.
124. Busca A, Locatelli F, Marmont F, Ceretto C, Falda M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2007;82:45-52.
125. Rodriguez V, Anderson PM, Trotz BA, Arndt CA, Allen JA, Khan SP. Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut. Pediatr Blood Cancer. 2007;49:212-215.
126. Sleight BS, Chan KW, Braun TM, Serrano A, Gilman AL. Infliximab for GVHD therapy in children. Bone Marrow Transplant. 2007;40:473-480.
127. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993;30:1443-1453.
128. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995;7:251-259.
129. Chiang KY, Abhyankar S, Bridges K, Godder K, Henslee-Downey JP. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation. 2002;73:665-667.
130. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 2004;15:255-273.
131. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med. 2005;353:1412-1413.
132. Majhail NS, Schiffer CA, Weisdorf DJ. Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006;12:789-791.
133. Magro L, Catteau B, Coiteux V, Bruno B, Jouet JP, Yakoub-Agha I. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. Bone Marrow Transplant. 2008;42:757-760.
134. Moreno-Romero JA, Fernandez-Aviles F, Carreras E, Rovira M, Martinez C, Mascaro JM Jr. Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease. Arch Dermatol. 2008;144:1106-1109.
135. Magro L, Mohty M, Catteau B, et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood. 2009;114:719-722.
136. Olivieri A, Locatelli F, Zecca M, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. 2009;114:709-718.
137. Stadler M, Ahlborn R, Kamal H, et al. Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease. Blood. 2009;114:3718-3719.
138. Saven A, Piro L. Newer purine analogues for the treatment of hairy-cell leukemia. N Engl J Med. 1994;330:691-697.
139. Higman MA, Vogelsang GB. Chronic graft versus host disease. Br J Haematol. 2004;125:435-454.
140. Bolanos-Meade J, Vogelsang GB. Novel strategies for steroidrefractory acute graft-versus-host disease. Curr Opin Hematol. 2005;12:40-44.
141. Jacobsohn DA, Gilman AL, Rademaker A, et al. Evaluation of pentostatin in corticosteroid-refractory chronic graft-versushost disease in children: a Pediatric Blood and Marrow Transplant Consortium study. Blood. 2009;114:4354-4360.
142. Wolff D, Steiner B, Hildebrandt G, Edinger M, Holler E. Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease. Curr Pharm Des. 2009;15:1974-1997.
143. Johnston A, Gudjonsson JE, Sigmundsdottir H, LudvikssonBR, ValdimarssonH. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005;114: 154-163.
144. de Lavallade H, Mohty M, Faucher C, Furst S, El Cheikh J, Blaise D. Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Haematologica. 2006;91:1438-1440.
145. Inagaki J, Nagatoshi Y, Hatano M, Isomura N, Sakiyama M, Okamura J. Low-dose MTX for the treatment of acute and chronic graft-versus-host disease in children. Bone Marrow Transplant. 2008;41:571-577.
146. Huang XJ, Jiang Q, Chen H, et al. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;36:343-348.
147. Giaccone L, Martin P, Carpenter P, et al. Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease. Bone Marrow Transplant. 2005;36: 337-341.
148. Wang Y, Xu LP, Liu DH, et al. First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate. Biol Blood Marrow Transplant. 2009;15:505-511.
149. Morgan SL, Baggott JE, Alarcon GS. Methotrexate in rheumatoid arthritis: folate supplementation should always be given. BioDrugs. 1997;8:164-175.
150. Pusic I, Pavletic SZ, Kessinger A, Tarantolo SR, Bishop MR. Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease. Bone Marrow Transplant. 2002;29:709-710.
151. Mayer J, Krejci M, Doubek M, et al. Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease. Bone Marrow Transplant. 2005;35:699-705.
152. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655-2666.
153. de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670-680.
154. Purcell IF, Bourke SJ, Marshall SM. Cyclophosphamide in severe steroid-resistant bronchiolitis obliterans organizing pneumonia. Respir Med. 1997;91:175-177.
155. Shinohara T, Hidaka T, Matsuki Y, et al. Rapidly progressive interstitial lung disease associated with dermatomyositis responding to intravenous cyclophosphamide pulse therapy. Intern Med. 1997;36:519-523.
156. Lee SJ, Wegner SA, McGarigle CJ, Bierer BE, Antin JH. Treatment of chronic graft-versus-host disease with clofazimine. Blood. 1997;89:2298-2302.
157. Rzepecki P, Barzal J, Sarosiek T, Oborska S, Szczylik C. How can we help patients with refractory chronic graft versus host disease-single centre experience. Neoplasma. 2007;54: 431-436.
158. Moreira V, De Medeiros BC, Bonfim CM, Pasquini R, De Medeiros CR. Methemoglobinemia secondary to clofazimine treatment for chronic graft-versus-host disease. Blood. 1998;92:4872-4873.
159. Bullorsky EO, Shanley CM, Stemmelin GR, et al. Total lymphoid irradiation for treatment of drug resistant chronic GVHD. Bone Marrow Transplant. 1993;11:75-76.
160. Perez-Simon JA, Encinas C, Silva F, et al. Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. Biol Blood Marrow Transplant. 2008;14:1163-1171.